Table 3.
Mutations, RRs, and LRP in Patients and Controls
| Mutation | PAC (n = 145) |
Controls (n = 5,318) |
LRP | PPMUT | RR | LRC | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | RR | 95% CI | |||||||||
| BRCA26174delT | 6 | 4.1 | 59 | 1.1 | 3.85 | 2.1 to 10.8 | 0.0131 | 0.011 | 3.85 | 0.049 | ||||
Abbreviations: RR, relative risk of pancreatic adenocarcinoma; PAC, pancreatic adenocarcinoma; LRP, lifetime risk of pancreatic adenocarcinoma in the general population; PPMUT, prevalence of mutations in controls; LRC, lifetime risk of pancreatic adenocarcinoma in the BRCA2 heterozygotes.